http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_210c50c8c037fdc3ac0c96a70d92c40d
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Decaudin |
| name | Didier Decaudin |
| given-name | Didier |
| organization-name | Authors' Affiliations: 1Institut Curie, Centre de Recherche; 2AgroParisTech/INRA UMR MIA 518, Paris; 3Translational Research Department; 4Breast Cancer Biology Group; 5Laboratory of Preclinical Investigation; 6Tumor Biology Department, Institut Curie Hospital; 7INSERM U830; 8INSERM U900; 9Mines ParisTech, Fontainebleau; 10Departments of Biostatistics and 11Medical Oncology; 12Reverse Phase Protein Array Platform; 13Platform of Molecular Biology Facilities; and 14Oncology Research and Development Unit, Institut de Recherches SERVIER, Croissy-sur-Seine, France; Authors' Affiliations: 1Institut Curie, Centre de Recherche; 2AgroParisTech/INRA UMR MIA 518, Paris; 3Translational Research Department; 4Breast Cancer Biology Group; 5Laboratory of Preclinical Investigation; 6Tumor Biology Department, Institut Curie Hospital; 7INSERM U830; 8INSERM U900; 9Mines ParisTech, Fontainebleau; 10Departments of Biostatistics and 11Medical Oncology; 12Reverse Phase Protein Array Platform; 13Platform of Molecular Biology Facilities; and 14Oncology Research and Development Unit, Institut de Recherches SERVIER, Croissy-sur-Seine, France; Authors' Affiliations: 1Institut Curie, Centre de Recherche; 2AgroParisTech/INRA UMR MIA 518, Paris; 3Translational Research Department; 4Breast Cancer Biology Group; 5Laboratory of Preclinical Investigation; 6Tumor Biology Department, Institut Curie Hospital; 7INSERM U830; 8INSERM U900; 9Mines ParisTech, Fontainebleau; 10Departments of Biostatistics and 11Medical Oncology; 12Reverse Phase Protein Array Platform; 13Platform of Molecular Biology Facilities; and 14Oncology Research and Development Unit, Institut de Recherches SERVIER, Croissy-sur-Seine, France; Authors' Affiliations: 1Institut Curie, Centre de Recherche; 2AgroParisTech/INRA UMR MIA 518, Paris; 3Translational Research Department; 4Breast Cancer Biology Group; 5Laboratory of Preclinical Investigation; 6Tumor Biology Department, Institut Curie Hospital; 7INSERM U830; 8INSERM U900; 9Mines ParisTech, Fontainebleau; 10Departments of Biostatistics and 11Medical Oncology; 12Reverse Phase Protein Array Platform; 13Platform of Molecular Biology Facilities; and 14Oncology Research and Development Unit, Institut de Recherches SERVIER, Croissy-sur-Seine, France Authors' Affiliations: 1Institut Curie; 2INSERM U830; Départements 3d'Oncologie Médicale, 4d'Imagerie Médicale, 5Biologie des Tumeurs, 6CIC-BT-507 INSERM; 7Département de Recherche Translationnelle, 8Laboratoire d'Investigation Préclinique, 9Département de Chirurgie, and 10INSERM U932, Paris, France; Authors' Affiliations: 1Institut Curie; 2INSERM U830; Départements 3d'Oncologie Médicale, 4d'Imagerie Médicale, 5Biologie des Tumeurs, 6CIC-BT-507 INSERM; 7Département de Recherche Translationnelle, 8Laboratoire d'Investigation Préclinique, 9Département de Chirurgie, and 10INSERM U932, Paris, France; Authors' Affiliations: 1Institut Curie; 2INSERM U830; Départements 3d'Oncologie Médicale, 4d'Imagerie Médicale, 5Biologie des Tumeurs, 6CIC-BT-507 INSERM; 7Département de Recherche Translationnelle, 8Laboratoire d'Investigation Préclinique, 9Département de Chirurgie, and 10INSERM U932, Paris, France Department of Hematology, and UMR 147 CNRS, Section de Recherche, Institut Curie, 75005 Paris, France. didier.decaudin@curie.net Authors' Affiliations: 1Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie; 2Department of Tumor Biology, Institut Curie; 3Institut Curie; 4Institut National de la Sante et de la Recherche Medicale, U900; 5Centre National de la Recherche Scientifique UMR146, Institut Curie; 6Department of Genetics, Institut Curie; 7Department of Visceral Surgery, Institut Curie; 8Department of Ophthalmological Oncology, Institut Curie; 9Department of Medical Oncology, Institut Curie; 10Department of Statistics, Institut Curie; 11Affymetrix Platform, Translational Research Department, Institut Curie; 12Translational Research Department, Institut Curie; 13Department of Clinical Hematology, Institut Curie, Paris, France and 14Ecole des Mines de Paris, Fontainebleau, France; Authors' Affiliations: 1Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie; 2Department of Tumor Biology, Institut Curie; 3Institut Curie; 4Institut National de la Sante et de la Recherche Medicale, U900; 5Centre National de la Recherche Scientifique UMR146, Institut Curie; 6Department of Genetics, Institut Curie; 7Department of Visceral Surgery, Institut Curie; 8Department of Ophthalmological Oncology, Institut Curie; 9Department of Medical Oncology, Institut Curie; 10Department of Statistics, Institut Curie; 11Affymetrix Platform, Translational Research Department, Institut Curie; 12Translational Research Department, Institut Curie; 13Department of Clinical Hematology, Institut Curie, Paris, France and 14Ecole des Mines de Paris, Fontainebleau, France Departments of 1Medical Oncology and; 3Laboratory of Preclinical Investigation, Translational Research Department; e Preclinical Investigation Laboratory, Institut Curie, Paris, France 1Translational Research Department, Institut Curie, PSL Research University, Paris, France.; 2Medical Oncology Department, Institut Curie, PSL Research University, Paris, France. Department of Clinical HematologyInstitut Curie, Paris, France; Laboratory of Preclinical InvestigationTranslational Research Department, Institut Curie, Paris, France Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France Translational Research Department Institut Curie PSL Research University Paris France; Medical Oncology Department Institut Curie Paris Cedex 05 France Authors' Affiliations: 1EMD Serono Research Institute, Billerica, Massachusetts; 2Preclinical Investigation Unit, Institut Curie - Translational Research Department, Hôpital; 3APHP Hôpital Saint-Louis, Unité d'Oncologie Moléculaire - Université Paris-Diderot, Sorbonne Paris Cité, CNRS UMR7212/INSERMU944; 4Medical Oncology Department, Institut Curie, Paris; 5National Veterinary School of Maisons Alfort, Maisons-Alfort; 6INRA, Phase Department, Nouzilly; and 7Oncogenetics Department, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France; Authors' Affiliations: 1EMD Serono Research Institute, Billerica, Massachusetts; 2Preclinical Investigation Unit, Institut Curie - Translational Research Department, Hôpital; 3APHP Hôpital Saint-Louis, Unité d'Oncologie Moléculaire - Université Paris-Diderot, Sorbonne Paris Cité, CNRS UMR7212/INSERMU944; 4Medical Oncology Department, Institut Curie, Paris; 5National Veterinary School of Maisons Alfort, Maisons-Alfort; 6INRA, Phase Department, Nouzilly; and 7Oncogenetics Department, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France From the Institut Langevin Ondes et Images, (CNRS UMR 7587), INSERM U979 Paris, France; Institut Curie, Centre de Recherche, Traffic, Signaling and Delivery Laboratory, Paris, France; CNRS UMR144, Paris, France; Institut Curie, Département du Transfert, Paris, France; Institut Curie, Department of Clinical Hematology, Paris, France; Fondation Pierre-Gilles de Gennes, Paris, France Translational Research Department, Laboratory of Preclinical Investigation, PSL University, Institut Curie, 26 rue d'Ulm, Paris 75248, France; Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, Paris 75248, France 1UMR144 Curie/Centre National de la Recherche Scientifique, Institut Curie, Paris, France; Department of Hematology, Institut Curie, Paris, France Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France 4Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.; 6Department of Medical Oncology, Institut Curie, Paris, France. Laboratory of Preclinical Investigation, Institut Curie, PSL Research University, 75005 Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France Laboratory of Preclinical Investigation, Institut Curie, 26 rue d'Ulm, F-75248 Paris, France From the Groupe d'Etude des Lymphomes de l'Adulte, Créteil, Paris, Nantes, Rouen, Caen, Lyon, and Le Mans, France, and Yvoir, Belgium. Institut Curie, PSL Research University, Translational Research Department, Preclinical Investigation Laboratory, Paris, France Laboratory of preclinical investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris Sciences & Lettres University Paris, Paris, France;; Department of Medical Oncology, Institut Curie, Paris, France; Department of Translational Research, Laboratory of Preclinical Investigation, Institut Curie, Paris-Saclay University, Paris; Judith Trotman and Jane Estell, Concord Hospital; Michael Fulham, Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney, Sydney; John Francis Seymour, Peter MacCallum Cancer Center and University of Melbourne, Melbourne; Cecily Forsyth, Wyong Hospital, Kanwal, Australia; Marion Fournier, Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Bénite; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut... Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, 1 Ave Claude Vellefaux 75010 Paris, France Institut Curie, Paris, France; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France; Department of Medical Oncology, Institut Curie, PSL University, Paris, France Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University Paris, 26 rue d’Ulm, CEDEX 05, 75248 Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, 75248 Paris, France Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France; These authors contributed equally to this work Laboratory of Preclinical Investigation, Translational Research Department, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France 8Department of Medical Oncology, Institut Curie, Paris, France From the Department of Clinical Hematology/Unité mixte de recherché (UMR) 144, Centre National de la Recherche Scientifique (CNRS), Institut Curie; the Department of Tumor Biology, Institut Curie; the Department of Radiation Oncology, Institut Curie; and the Department of Ophthalmology, Institut Curie, Paris, France. Laboratoire d'Investigation Pré ‐Clinique/Service d'Hématologie Clinique Institut Curie Paris France Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France.; Medical Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France. Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France; Curie, Department of Medical Oncology, PSL Research University, Paris, France |
Incoming Links
Total number of triples: 169.